Predictive Factors for Survival in Aggressive Meningiomas

Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05793034

Acronym

23Men

Enrollment

250

Registered

2023-03-31

Start date

2021-01-07

Completion date

2027-01-07

Last updated

2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplastic Meningioma, Meningioma, Meningioma Atypical

Brief summary

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

Interventions

DIAGNOSTIC_TESTBiological biomarker assessment

IHC, PCR, NGS, methylome

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient operated for atypical (grade 2) meningioma; or 2. Patient operated for anaplastic (grade 3) meningioma; 3. Timeframe for surgery, 1999-2019

Exclusion criteria

1\) Patient lost at follow-up

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival (RFS)	5 years on average	Correlation from biomolecular data and RFS

Secondary

Measure	Time frame	Description
Overall survival (OS)	5 years on average	Correlation from biomolecular data and OS

Countries

Italy

Contacts

Primary ContactAlessandro Olivi, MD

alessandro.olivi@policlinicogemelli.it+39 06 3015 4120

Backup ContactRina Di Bonaventura, MD

rina.dibonaventura@guest.policlinicogemelli.it+39 06 3015 1

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026